Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
January 14, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – Alto Neuroscience, biopharma, neurology, neuropsychiatric disorders, precision medicine, treatment resistant depression
Issued and pending claims expected to protect ALTO-207 into the mid-2040s
14 January 2026 — California, US — Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole. The newly issued patent claims further strengthen the company’s growing intellectual property estate supporting ALTO-207, a differentiated investigational therapy being developed for patients with treatment-resistant depression.
The company believes that, together with previously issued patents and pending applications in the U.S. and internationally, the ALTO-207 intellectual property portfolio provides protection extending into the mid-2040s, reinforcing the long-term commercial opportunity for the program.
“This patent issuance meaningfully strengthens the foundation of our ALTO-207 franchise,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Robust and durable intellectual property is critical as we advance precision-based treatments for depression, and this milestone reflects both the novelty of ALTO-207 and our commitment to building long-term value for patients, clinicians, and shareholders. We believe the breadth and duration of our issued and pending claims position ALTO-207 as a potentially enduring asset in the treatment landscape for depression.”
The Company believes the issuance of this patent reinforces Alto’s strategy of building a portfolio of differentiated, innovative, precision-driven assets protected by robust intellectual property estates.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Visit: altoneuroscience.com.
